Mayo Clinic07.30.19
Mayo Clinic and Boston Scientific Corp. have launched a new venture to accelerate the development of medical technology and new minimally invasive treatments for many health conditions that impede quality and longevity of life.
The accelerator, known as Motion Medical, will have its research facilities in One Discovery Square, the bioscience center in the Discovery Square research district. Both parties have committed millions of dollars over three years to develop and bring new solutions to the market to address unmet medical needs.
"Mayo Clinic is committed to accelerating the pace of discoveries to bring new technologies and treatments to patients faster," said Gianrico Farrugia, M.D., president and CEO of Mayo Clinic. "This collaboration and others like it will continue to strengthen Rochester and Minnesota as a biomedical innovation and economic powerhouse."
This venture is another step forward in the collaboration between Mayo Clinic and Boston Scientific Corp., combining Mayo Clinic's world-class clinical experience and patient care with Boston Scientific's extraordinary engineering, innovation and business expertise.
The accelerator, spreading over 1,800 square feet, will be a key tenant in One Discovery Square, developed by Mortenson. The building anchors the 16-block Discovery Square research district for the $5.6 billion Destination Medical Center economic development initiative in Rochester. The accelerator is expected to open in the fall.
"This collaboration between Mayo Clinic and Boston Scientific builds on our experience working together to support the shared goal of advancing patient-centered innovation," said Mike Mahoney, chairman and CEO, Boston Scientific. "This approach combines the unique strengths of our two organizations, and we look forward to working together to solve complex health care challenges."
Mayo Clinic and Boston Scientific Corp. have collaborated for nearly a decade to develop new devices and technologies in areas such as interventional cardiology, neuromodulation, and urology. Together the companies have filed eight patent applications and collaborated on two first-in-human clinical trials.
The accelerator, known as Motion Medical, will have its research facilities in One Discovery Square, the bioscience center in the Discovery Square research district. Both parties have committed millions of dollars over three years to develop and bring new solutions to the market to address unmet medical needs.
"Mayo Clinic is committed to accelerating the pace of discoveries to bring new technologies and treatments to patients faster," said Gianrico Farrugia, M.D., president and CEO of Mayo Clinic. "This collaboration and others like it will continue to strengthen Rochester and Minnesota as a biomedical innovation and economic powerhouse."
This venture is another step forward in the collaboration between Mayo Clinic and Boston Scientific Corp., combining Mayo Clinic's world-class clinical experience and patient care with Boston Scientific's extraordinary engineering, innovation and business expertise.
The accelerator, spreading over 1,800 square feet, will be a key tenant in One Discovery Square, developed by Mortenson. The building anchors the 16-block Discovery Square research district for the $5.6 billion Destination Medical Center economic development initiative in Rochester. The accelerator is expected to open in the fall.
"This collaboration between Mayo Clinic and Boston Scientific builds on our experience working together to support the shared goal of advancing patient-centered innovation," said Mike Mahoney, chairman and CEO, Boston Scientific. "This approach combines the unique strengths of our two organizations, and we look forward to working together to solve complex health care challenges."
Mayo Clinic and Boston Scientific Corp. have collaborated for nearly a decade to develop new devices and technologies in areas such as interventional cardiology, neuromodulation, and urology. Together the companies have filed eight patent applications and collaborated on two first-in-human clinical trials.
